Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study

BACKGROUND: Globally, recommendations are expanding for third (booster) doses of BNT162b2 (Pfizer–BioNTech). In the United States, as of November 19, 2021, boosters were recommended for all adults aged 18 years and older. We evaluated the effectiveness of a third dose of BNT162b2 among adults in a l...

Descripción completa

Detalles Bibliográficos
Autores principales: Tartof, Sara Y., Slezak, Jeff M., Puzniak, Laura, Hong, Vennis, Frankland, Timothy B., Ackerson, Bradley K., Takhar, Harpreet S., Ogun, Oluwaseye A., Simmons, Sarah R., Zamparo, Joann M., Gray, Sharon, Valluri, Srinivas R., Pan, Kaije, Jodar, Luis, McLaughlin, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841530/
https://www.ncbi.nlm.nih.gov/pubmed/35187521
http://dx.doi.org/10.1016/j.lana.2022.100198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841530/
https://www.ncbi.nlm.nih.gov/pubmed/35187521
http://dx.doi.org/10.1016/j.lana.2022.100198

Ejemplares similares